Latest news
Eli Lilly: 'Strong Buy' On Retatrutide Obesity Drug And EBGLYSS Maintenance Label Expansion - Seeking AlphaSeeking Alpha · Fri, 07 Aug 2026 22:29:17 GMTEli Lilly: Fine Q2 2026 Results, But Alertness Required (NYSE:LLY) - Seeking AlphaSeeking Alpha · Thu, 06 Aug 2026 21:42:40 GMTEli Lilly Q2: Strong Results Further Strengthen The Investment Thesis (NYSE:LLY) - Seeking AlphaSeeking Alpha · Thu, 06 Aug 2026 06:09:31 GMTEli Lilly and Company 2026 Q2 - Results - Earnings Call Presentation (NYSE:LLY) 2026-08-05 - Seeking AlphaSeeking Alpha · Wed, 05 Aug 2026 20:31:47 GMTEli Lilly Q2 Earnings Review: Breath-Taking Results Mean Higher Ceiling On Stock Price Target - Seeking AlphaSeeking Alpha · Wed, 05 Aug 2026 16:28:00 GMTEli Lilly stock jumps after Q2 beat driven by GLP-1s (LLY:NYSE) - Seeking AlphaSeeking Alpha · Wed, 05 Aug 2026 11:30:02 GMTEli Lilly's obesity momentum faces another earnings test (LLY:NYSE) - Seeking AlphaSeeking Alpha · Tue, 04 Aug 2026 15:46:29 GMT